Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

ERG deletions in childhood acute lymphoblastic leukemia with DUX4 rearrangements are mostly polyclonal, prognostically relevant and their detection rate strongly depends on screening method sensitivity.

Zaliova M, Potuckova E, Hovorkova L, Musilova A, Winkowska L, Fiser K, Stuchly J, Mejstrikova E, Starkova J, Zuna J, Stary J, Trka J.

Haematologica. 2019 Jul;104(7):1407-1416. doi: 10.3324/haematol.2018.204487. Epub 2019 Jan 10.

2.

Structure-Activity Relationships of Nitro-Substituted Aroylhydrazone Iron Chelators with Antioxidant and Antiproliferative Activities.

Hrušková K, Potůčková E, Opálka L, Hergeselová T, Hašková P, Kovaříková P, Šimůnek T, Vávrová K.

Chem Res Toxicol. 2018 Jun 18;31(6):435-446. doi: 10.1021/acs.chemrestox.7b00324. Epub 2018 May 23.

PMID:
29766723
3.

Two novel fusion genes, AIF1L-ETV6 and ABL1-AIF1L, result together with ETV6-ABL1 from a single chromosomal rearrangement in acute lymphoblastic leukemia with prenatal origin.

Lukes J Jr, Potuckova E, Sramkova L, Stary J, Starkova J, Trka J, Votava F, Zuna J, Zaliova M.

Genes Chromosomes Cancer. 2018 Sep;57(9):471-477. doi: 10.1002/gcc.6. Epub 2018 Jul 30.

PMID:
29726059
4.

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology.

Hovorkova L, Zaliova M, Venn NC, Bleckmann K, Trkova M, Potuckova E, Vaskova M, Linhartova J, Machova Polakova K, Fronkova E, Muskovic W, Giles JE, Shaw PJ, Cario G, Sutton R, Stary J, Trka J, Zuna J.

Blood. 2017 May 18;129(20):2771-2781. doi: 10.1182/blood-2016-11-749978. Epub 2017 Mar 22.

5.

Intragenic ERG Deletions Do Not Explain the Biology of ERG-Related Acute Lymphoblastic Leukemia.

Potuckova E, Zuna J, Hovorkova L, Starkova J, Stary J, Trka J, Zaliova M.

PLoS One. 2016 Aug 5;11(8):e0160385. doi: 10.1371/journal.pone.0160385. eCollection 2016.

6.

Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications.

Hrušková K, Potůčková E, Hergeselová T, Liptáková L, Hašková P, Mingas P, Kovaříková P, Šimůnek T, Vávrová K.

Eur J Med Chem. 2016 Sep 14;120:97-110. doi: 10.1016/j.ejmech.2016.05.015. Epub 2016 May 7.

PMID:
27187862
7.

Corrigendum to: "Proteomic investigation of embryonic rat heart-derived H9c2 cell line sheds new light on the molecular phenotype of the popular cell model" [Exp. Cell Res. 339 2 (2015) 174-186].

Lenčo J, Lenčová-Popelová O, Link M, Jirkovská A, Tambor V, Potůčková E, Stulík J, Šimůnek T, Štěrba M.

Exp Cell Res. 2016 May 1;343(2):267. doi: 10.1016/j.yexcr.2016.02.007. Epub 2016 Apr 4. No abstract available.

PMID:
27155561
8.

Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents.

Sestak V, Stariat J, Cermanova J, Potuckova E, Chladek J, Roh J, Bures J, Jansova H, Prusa P, Sterba M, Micuda S, Simunek T, Kalinowski DS, Richardson DR, Kovarikova P.

Oncotarget. 2015 Dec 15;6(40):42411-28. doi: 10.18632/oncotarget.6389.

9.

Proteomic investigation of embryonic rat heart-derived H9c2 cell line sheds new light on the molecular phenotype of the popular cell model.

Lenčo J, Lenčová-Popelová O, Link M, Jirkovská A, Tambor V, Potůčková E, Stulík J, Šimůnek T, Štěrba M.

Exp Cell Res. 2015 Dec 10;339(2):174-86. doi: 10.1016/j.yexcr.2015.10.020. Epub 2015 Nov 5. Erratum in: Exp Cell Res. 2016 May 1;343 (2):267.

PMID:
26515555
10.

In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites.

Potůčková E, Roh J, Macháček M, Sahni S, Stariat J, Šesták V, Jansová H, Hašková P, Jirkovská A, Vávrová K, Kovaříková P, Kalinowski DS, Richardson DR, Šimůnek T.

PLoS One. 2015 Oct 13;10(10):e0139929. doi: 10.1371/journal.pone.0139929. eCollection 2015.

11.

Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties.

Potůčková E, Hrušková K, Bureš J, Kovaříková P, Špirková IA, Pravdíková K, Kolbabová L, Hergeselová T, Hašková P, Jansová H, Macháček M, Jirkovská A, Richardson V, Lane DJ, Kalinowski DS, Richardson DR, Vávrová K, Šimůnek T.

PLoS One. 2014 Nov 13;9(11):e112059. doi: 10.1371/journal.pone.0112059. eCollection 2014.

12.

Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships.

Serda M, Kalinowski DS, Rasko N, Potůčková E, Mrozek-Wilczkiewicz A, Musiol R, Małecki JG, Sajewicz M, Ratuszna A, Muchowicz A, Gołąb J, Simůnek T, Richardson DR, Polanski J.

PLoS One. 2014 Oct 16;9(10):e110291. doi: 10.1371/journal.pone.0110291. eCollection 2014.

13.

Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.

Jansová H, Macháček M, Wang Q, Hašková P, Jirkovská A, Potůčková E, Kielar F, Franz KJ, Simůnek T.

Free Radic Biol Med. 2014 Sep;74:210-21. doi: 10.1016/j.freeradbiomed.2014.06.019. Epub 2014 Jun 30.

14.

Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs.

Potuckova E, Jansova H, Machacek M, Vavrova A, Haskova P, Tichotova L, Richardson V, Kalinowski DS, Richardson DR, Simunek T.

PLoS One. 2014 Feb 20;9(2):e88754. doi: 10.1371/journal.pone.0088754. eCollection 2014.

Supplemental Content

Loading ...
Support Center